Q3 FY2026 · ended Sep 30, 2026 · Revenue $395,000, +359.3% YoY · Filed Nov 5, 2026
Pulse Biosciences, Inc. (PLSE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $395,000 and a net loss of $23.1 million. Free cash flow was -$15.4 million. As of Sep 30, 2026 it held $36.7 million in cash and investments and $6.4 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PLSE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1625101
- Former names
- Electroblate, Inc. (until Nov 13, 2014)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $395,000 | $434,000 | $401,000 | $264,000 | $86,000 |
| Operating income | -$24.3M | -$25.3M | -$19.1M | -$18.3M | -$20.4M |
| Net income | -$23.1M | -$24.7M | -$18.6M | -$17.4M | -$19.4M |
| Operating cash flow | -$15.3M | -$18.7M | -$14.6M | -$14.8M | -$13.0M |
| Free cash flow | -$15.4M | -$18.8M | -$14.6M | -$14.9M | -$13.1M |
| Total assets | $201.6M | $115.6M | $81.6M | $94.5M | $108.8M |
| Total liabilities | $18.0M | $16.1M | $15.3M | $13.9M | $16.1M |
| Stockholders' equity | $183.6M | $99.5M | $66.3M | $80.7M | $92.7M |
| Cash and investments | $36.7M | $101.6M | $68.3M | $80.7M | $95.2M |
| Total debt | $6.4M | $6.8M | $7.2M | $7.5M | $7.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
All 641 Pulse Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.